Bioprocessing Global Market Opportunities and Strategies to 2034

This report describes and explains the bioprocessing market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global bioprocessing market reached a value of nearly $62.34 billion in 2024, having grown at a compound annual growth rate (CAGR) of 12.93% since 2019. The market is expected to grow from $62.34 billion in 2024 to $122.67 billion in 2029 at a rate of 14.50%. The market is then expected to grow at a CAGR of 13.45% from 2029 and reach $230.55 billion in 2034.

Growth in the historic period resulted from government support in biotechnology, expansion of pharmaceutical and biotechnology industries, increasing investments in biotech R&D and growing demand for personalized medicine. Factors that negatively affected growth in the historic period were high energy and water consumption in manufacturing and skilled workforce shortage.

Going forward, expansion of contract development and manufacturing organizations (CDMOs), rise in rare disease and orphan drug development, demand for cell and gene therapies and rising prevalence of chronic diseases will drive the growth. Factors that could hinder the growth of the bioprocessing market in the future include impact of trade war and tariff, long development and scale-up timelines and risk of contamination and process failures.

North America was the largest region in the bioprocessing market, accounting for 43.40% or $27.05 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the bioprocessing market will be Asia Pacific and Middle East where growth will be at CAGRs of 16.22% and 15.63% respectively. These will be followed by Eastern Europe and North America where the markets are expected to grow at CAGRs of 15.40% and 14.10% respectively.

The global bioprocessing market is fairly fragmented, with a large number of small players operating in the market. The top ten competitors in the market made up to 23.04% of the total market in 2024. Sartorius AG (Novasep) was the largest competitor with a 4.67% share of the market, followed by Thermo Fisher Scientific Inc with 3.40%, Danaher Corporation with 2.86%, Merck KGaA (MilliporeSigma) with 2.56%, Lonza Group AG with 2.44%, Agilent Technologies Inc with 1.82%, Cytiva AB with 1.51%, Bristol Myers Squibb Company with 1.36%, GE Healthcare Technologies Inc with 1.33% and Pfizer Inc with 1.10%.

The bioprocessing market is segmented by type into upstream processing and downstream processing. The downstream processing market was the largest segment of the bioprocessing market segmented by type, accounting for 58.06% or $36.19 billion of the total in 2024. Going forward, the downstream processing segment is expected to be the fastest growing segment in the bioprocessing market segmented by type, at a CAGR of 14.87% during 2024-2029.

The bioprocessing market is segmented by application into monoclonal antibodies, cell and gene therapy, vaccines and other applications. The monoclonal antibodies market was the largest segment of the bioprocessing market segmented by application, accounting for 39.86% or $24.85 billion of the total in 2024. Going forward, the cell and gene therapy segment is expected to be the fastest growing segment in the bioprocessing market segmented by application, at a CAGR of 18.72% during 2024-2029.

The bioprocessing market is segmented by end user into biopharmaceutical companies, contract manufacturing organizations, academic research institutes and other end users. The biopharmaceutical companies market was the largest segment of the bioprocessing market segmented by end user, accounting for 59.97% or $37.38 billion of the total in 2024. Going forward, the contract manufacturing organizations segment is expected to be the fastest growing segment in the bioprocessing market segmented by end user, at a CAGR of 15.41% during 2024-2029.

The bioprocessing market is segmented by scale of operation into commercial-scale, preclinical and clinical. The commercial-scale market was the largest segment of the bioprocessing market segmented by scale of operation, accounting for 69.65% or $43.42 billion of the total in 2024. Going forward, the commercial-scale segment is expected to be the fastest growing segment in the bioprocessing market segmented by scale of operation, at a CAGR of 15.41% during 2024-2029.

The bioprocessing market is segmented by product into equipment, consumables and services. The consumables market was the largest segment of the bioprocessing market segmented by product, accounting for 60.10% or $37.46 billion of the total in 2024. Going forward, the consumables segment is expected to be the fastest growing segment in the bioprocessing market segmented by product, at a CAGR of 15.59% during 2024-2029.

The top opportunities in the bioprocessing market segmented by type will arise in the downstream processing segment, which will gain $36.19 billion of global annual sales by 2029. The top opportunities in the bioprocessing market segmented by application will arise in the cell and gene therapy segment, which will gain $25.71 billion of global annual sales by 2029. The top opportunities in the bioprocessing market segmented by end user will arise in the biopharmaceutical companies segment, which will gain $36.37 billion of global annual sales by 2029. The top opportunities in the bioprocessing market segmented by scale of operation will arise in the commercial-scale segment, which will gain $45.48 billion of global annual sales by 2029. The top opportunities in the bioprocessing market segmented by product will arise in the consumables segment, which will gain $39.83 billion of global annual sales by 2029. The bioprocessing market size will gain the most in the USA at $23.49 billion.

Market-trend-based strategies for the bioprocessing market include focus on merging spectral cytometry with real-time imaging, focus on expansion of automated cell and gene therapy manufacturing in emerging markets, focus on development of refining tangential flow filtration (TFF) consumables, focus on shift toward animal-free and in vitro pyrogen testing, focus on advancement of high-parameter spectral flow cytometry for drug discovery & cellular analysis, focus on introduction of the CHO edge system Gen-4 for next-gen cell line development and focus on development of rapid animal-free bacterial endotoxin test.

Player-adopted strategies in the bioprocessing market include focus on expanding operational capabilities through partnerships, focus on expanding business expertise through new facilities, focus on expanding operational capabilities through new launches.

To take advantage of the opportunities, the analyst recommends the bioprocessing market companies to focus on integrated spectral cytometry and real-time imaging to drive high-value research adoption, focus on automated cell and gene therapy expansion in emerging markets, focus on advancing TFF consumables for usability and sustainability gains, focus on enabling animal-free and in vitro pyrogen testing adoption, focus on advancing high-parameter spectral cytometry for drug discovery and cell analysis, focus on accelerating CHO cell line engineering with integrated high-throughput systems, focus on scaling animal-free endotoxin testing to strengthen quality and sustainability, focus on downstream processing to capture highest growth and quality demand, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2B promotions, participate in trade shows and events, focus on cell and gene therapies to capture strongest growth and innovation demand and focus on contract manufacturing organizations to maximize growth and outsourcing demand.